AU2012206621B2 - Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions - Google Patents
Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions Download PDFInfo
- Publication number
- AU2012206621B2 AU2012206621B2 AU2012206621A AU2012206621A AU2012206621B2 AU 2012206621 B2 AU2012206621 B2 AU 2012206621B2 AU 2012206621 A AU2012206621 A AU 2012206621A AU 2012206621 A AU2012206621 A AU 2012206621A AU 2012206621 B2 AU2012206621 B2 AU 2012206621B2
- Authority
- AU
- Australia
- Prior art keywords
- liquid medium
- drug
- suspension
- particles
- diafiltration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161431942P | 2011-01-12 | 2011-01-12 | |
| US61/431,942 | 2011-01-12 | ||
| PCT/EP2012/050336 WO2012095439A1 (en) | 2011-01-12 | 2012-01-11 | Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2012206621A1 AU2012206621A1 (en) | 2013-07-04 |
| AU2012206621B2 true AU2012206621B2 (en) | 2017-04-27 |
Family
ID=45478323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012206621A Active AU2012206621B2 (en) | 2011-01-12 | 2012-01-11 | Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9066864B2 (enExample) |
| EP (1) | EP2663287A1 (enExample) |
| JP (1) | JP5934719B2 (enExample) |
| CN (1) | CN103347499B (enExample) |
| AU (1) | AU2012206621B2 (enExample) |
| BR (1) | BR112013016851B1 (enExample) |
| CA (1) | CA2823972C (enExample) |
| MX (1) | MX346749B (enExample) |
| SG (2) | SG10201807631SA (enExample) |
| WO (1) | WO2012095439A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6478959B2 (ja) * | 2016-09-07 | 2019-03-06 | 株式会社富士薬品 | 粒子含有組成物を製造するためのシステム及び方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004037265A1 (en) * | 2002-10-25 | 2004-05-06 | Akzo Nobel N.V. | Prolonged release pharmaceutical composition |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6340580B1 (en) | 1999-05-12 | 2002-01-22 | Metabolix, Inc. | Methods for purifying polyhydroxy alkanoates |
| WO2001021290A1 (en) * | 1999-09-17 | 2001-03-29 | Danish Separation Systems As | A method and an apparatus for continuous cross-flow diafiltration |
| US20040256749A1 (en) * | 2000-12-22 | 2004-12-23 | Mahesh Chaubal | Process for production of essentially solvent-free small particles |
| WO2003055469A1 (en) * | 2001-12-21 | 2003-07-10 | Celator Technologies Inc. | Improved polymer-lipid delivery vehicles |
| WO2003063877A1 (en) | 2002-02-01 | 2003-08-07 | Akzo Nobel N.V. | Cefquinome composition for intra-mammary administration in cattle |
| ITMI20022674A1 (it) | 2002-12-18 | 2004-06-19 | Chiesi Farma Spa | Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione. |
| WO2011072218A2 (en) * | 2009-12-11 | 2011-06-16 | Bind Biosciences | Stable formulations for lyophilizing therapeutic particles |
-
2012
- 2012-01-11 AU AU2012206621A patent/AU2012206621B2/en active Active
- 2012-01-11 CN CN201280005390.0A patent/CN103347499B/zh active Active
- 2012-01-11 SG SG10201807631SA patent/SG10201807631SA/en unknown
- 2012-01-11 WO PCT/EP2012/050336 patent/WO2012095439A1/en not_active Ceased
- 2012-01-11 BR BR112013016851-0A patent/BR112013016851B1/pt active IP Right Grant
- 2012-01-11 US US13/979,231 patent/US9066864B2/en active Active
- 2012-01-11 EP EP12700273.1A patent/EP2663287A1/en not_active Withdrawn
- 2012-01-11 JP JP2013548820A patent/JP5934719B2/ja active Active
- 2012-01-11 MX MX2013008118A patent/MX346749B/es active IP Right Grant
- 2012-01-11 CA CA2823972A patent/CA2823972C/en active Active
- 2012-01-11 SG SG2013053764A patent/SG191963A1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004037265A1 (en) * | 2002-10-25 | 2004-05-06 | Akzo Nobel N.V. | Prolonged release pharmaceutical composition |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013016851B1 (pt) | 2021-08-31 |
| US20130281425A1 (en) | 2013-10-24 |
| WO2012095439A1 (en) | 2012-07-19 |
| SG10201807631SA (en) | 2018-10-30 |
| US9066864B2 (en) | 2015-06-30 |
| EP2663287A1 (en) | 2013-11-20 |
| CN103347499A (zh) | 2013-10-09 |
| BR112013016851A2 (pt) | 2016-10-04 |
| CN103347499B (zh) | 2017-04-05 |
| CA2823972C (en) | 2019-05-28 |
| CA2823972A1 (en) | 2012-07-19 |
| JP5934719B2 (ja) | 2016-06-15 |
| JP2014502624A (ja) | 2014-02-03 |
| SG191963A1 (en) | 2013-08-30 |
| MX346749B (es) | 2017-03-29 |
| MX2013008118A (es) | 2013-08-12 |
| AU2012206621A1 (en) | 2013-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7203078B2 (ja) | 粒子の連続製造方法 | |
| CA2868676C (en) | Production of near monodisperse particles using milling and membrane separation | |
| AU2015295073B2 (en) | A method of preparing amorphous solid dispersion in submicron range by co-precipitation | |
| KR100200061B1 (ko) | 표면이 변형된 미립자 형태의 약제 | |
| US7468151B2 (en) | Method for the preparation of purified microparticles | |
| NO325475B1 (no) | Farmasoytisk preparat som omfatter ceftiofurhydroklorid, en biokompatibel olje og vann. | |
| WO2010032434A1 (ja) | 医療用複合有機化合物粉体、その製造方法ならびに懸濁液 | |
| AU2012206621B2 (en) | Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions | |
| WO2012095438A1 (en) | Particles and suspensions of cephalosporin antibiotics | |
| CN118453513B (zh) | 一种β-内酰胺酶抑制剂液体制剂的制备工艺 | |
| HK40125885A (zh) | 用於高度浓缩的核酸组合物的降低粘度的赋形剂及其组合 | |
| JP2025525153A (ja) | 高濃縮核酸組成物のための粘度を低減させる賦形剤およびそれらの組み合わせ | |
| CN120379751A (zh) | 提供用于形成微囊泡的脂质体溶液的方法 | |
| AU2006212177A1 (en) | Method of purifying a surfactant by ultrafiltration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |